Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer
BackgroundProstate cancer (PCa) is the most common malignant male neoplasm in the American male population. Our prior studies have demonstrated that protein phosphatase 1 regulatory subunit 12A (PPP1R12A) could be an efficient prognostic factor in patients with PCa, promoting further investigation....
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2021.703210/full |
id |
doaj-2eff17c21eac422b9e1ab0df666f20aa |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zhihao Zou Zhihao Zou Ren Liu Yingke Liang Rui Zhou Qishan Dai Zhaodong Han Minyao Jiang Yangjia Zhuo Yixun Zhang Yuanfa Feng Xuejin Zhu Shanghua Cai Jundong Lin Zhenfeng Tang Weide Zhong Weide Zhong Weide Zhong Weide Zhong Yuxiang Liang Yuxiang Liang Yuxiang Liang |
spellingShingle |
Zhihao Zou Zhihao Zou Ren Liu Yingke Liang Rui Zhou Qishan Dai Zhaodong Han Minyao Jiang Yangjia Zhuo Yixun Zhang Yuanfa Feng Xuejin Zhu Shanghua Cai Jundong Lin Zhenfeng Tang Weide Zhong Weide Zhong Weide Zhong Weide Zhong Yuxiang Liang Yuxiang Liang Yuxiang Liang Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer Frontiers in Genetics prostate cancer protein phosphatase 1 regulatory subunit 12A metabolism gene signature prognostic model |
author_facet |
Zhihao Zou Zhihao Zou Ren Liu Yingke Liang Rui Zhou Qishan Dai Zhaodong Han Minyao Jiang Yangjia Zhuo Yixun Zhang Yuanfa Feng Xuejin Zhu Shanghua Cai Jundong Lin Zhenfeng Tang Weide Zhong Weide Zhong Weide Zhong Weide Zhong Yuxiang Liang Yuxiang Liang Yuxiang Liang |
author_sort |
Zhihao Zou |
title |
Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer |
title_short |
Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer |
title_full |
Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer |
title_fullStr |
Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer |
title_full_unstemmed |
Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer |
title_sort |
identification and validation of a ppp1r12a-related five-gene signature associated with metabolism to predict the prognosis of patients with prostate cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Genetics |
issn |
1664-8021 |
publishDate |
2021-08-01 |
description |
BackgroundProstate cancer (PCa) is the most common malignant male neoplasm in the American male population. Our prior studies have demonstrated that protein phosphatase 1 regulatory subunit 12A (PPP1R12A) could be an efficient prognostic factor in patients with PCa, promoting further investigation. The present study attempted to construct a gene signature based on PPP1R12A and metabolism-related genes to predict the prognosis of PCa patients.MethodsThe mRNA expression profiles of 499 tumor and 52 normal tissues were extracted from The Cancer Genome Atlas (TCGA) database. We selected differentially expressed PPP1R12A-related genes among these mRNAs. Tandem affinity purification-mass spectrometry was used to identify the proteins that directly interact with PPP1R12A. Gene set enrichment analysis (GSEA) was used to extract metabolism-related genes. Univariate Cox regression analysis and a random survival forest algorithm were used to confirm optimal genes to build a prognostic risk model.ResultsWe identified a five-gene signature (PPP1R12A, PTGS2, GGCT, AOX1, and NT5E) that was associated with PPP1R12A and metabolism in PCa, which effectively predicted disease-free survival (DFS) and biochemical relapse-free survival (BRFS). Moreover, the signature was validated by two internal datasets from TCGA and one external dataset from the Gene Expression Omnibus (GEO).ConclusionThe five-gene signature is an effective potential factor to predict the prognosis of PCa, classifying PCa patients into high- and low-risk groups, which might provide potential novel treatment strategies for these patients. |
topic |
prostate cancer protein phosphatase 1 regulatory subunit 12A metabolism gene signature prognostic model |
url |
https://www.frontiersin.org/articles/10.3389/fgene.2021.703210/full |
work_keys_str_mv |
AT zhihaozou identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT zhihaozou identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT renliu identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT yingkeliang identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT ruizhou identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT qishandai identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT zhaodonghan identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT minyaojiang identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT yangjiazhuo identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT yixunzhang identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT yuanfafeng identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT xuejinzhu identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT shanghuacai identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT jundonglin identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT zhenfengtang identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT weidezhong identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT weidezhong identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT weidezhong identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT weidezhong identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT yuxiangliang identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT yuxiangliang identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer AT yuxiangliang identificationandvalidationofappp1r12arelatedfivegenesignatureassociatedwithmetabolismtopredicttheprognosisofpatientswithprostatecancer |
_version_ |
1721208408364810240 |
spelling |
doaj-2eff17c21eac422b9e1ab0df666f20aa2021-08-13T10:34:00ZengFrontiers Media S.A.Frontiers in Genetics1664-80212021-08-011210.3389/fgene.2021.703210703210Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate CancerZhihao Zou0Zhihao Zou1Ren Liu2Yingke Liang3Rui Zhou4Qishan Dai5Zhaodong Han6Minyao Jiang7Yangjia Zhuo8Yixun Zhang9Yuanfa Feng10Xuejin Zhu11Shanghua Cai12Jundong Lin13Zhenfeng Tang14Weide Zhong15Weide Zhong16Weide Zhong17Weide Zhong18Yuxiang Liang19Yuxiang Liang20Yuxiang Liang21Department of Geriatrics, The Second Affiliated Hospital of South China University of Technology, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaGuangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaDepartment of Urology, Huadu District People’s Hospital, Southern Medical University, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaUrology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaUrology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaGuangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaUrology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, ChinaState Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, ChinaDepartment of Geriatrics, The Second Affiliated Hospital of South China University of Technology, Guangzhou, ChinaGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, ChinaDepartment of Urology, Huizhou Municipal Central Hospital, Huizhou, ChinaBackgroundProstate cancer (PCa) is the most common malignant male neoplasm in the American male population. Our prior studies have demonstrated that protein phosphatase 1 regulatory subunit 12A (PPP1R12A) could be an efficient prognostic factor in patients with PCa, promoting further investigation. The present study attempted to construct a gene signature based on PPP1R12A and metabolism-related genes to predict the prognosis of PCa patients.MethodsThe mRNA expression profiles of 499 tumor and 52 normal tissues were extracted from The Cancer Genome Atlas (TCGA) database. We selected differentially expressed PPP1R12A-related genes among these mRNAs. Tandem affinity purification-mass spectrometry was used to identify the proteins that directly interact with PPP1R12A. Gene set enrichment analysis (GSEA) was used to extract metabolism-related genes. Univariate Cox regression analysis and a random survival forest algorithm were used to confirm optimal genes to build a prognostic risk model.ResultsWe identified a five-gene signature (PPP1R12A, PTGS2, GGCT, AOX1, and NT5E) that was associated with PPP1R12A and metabolism in PCa, which effectively predicted disease-free survival (DFS) and biochemical relapse-free survival (BRFS). Moreover, the signature was validated by two internal datasets from TCGA and one external dataset from the Gene Expression Omnibus (GEO).ConclusionThe five-gene signature is an effective potential factor to predict the prognosis of PCa, classifying PCa patients into high- and low-risk groups, which might provide potential novel treatment strategies for these patients.https://www.frontiersin.org/articles/10.3389/fgene.2021.703210/fullprostate cancerprotein phosphatase 1 regulatory subunit 12Ametabolismgene signatureprognostic model |